NCT01365624View on ClinicalTrials.gov

Safety and Pharmacokinetics Study of Intranasal Ketorolac in Elderly and Nonelderly Adult Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

April 30, 2008

Study Completion Date

July 31, 2008

Conditions
Healthy Subjects
Interventions
DRUG

Ketorolac tromethamine

Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)

Trial Locations (1)

33126

Seaview Research, Miami

Sponsors
All Listed Sponsors
lead

American Regent, Inc.

INDUSTRY